If you invested in R1 RCM and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses »
CLASS PERIOD
N/A
LEAD PLAINTIFF DEADLINE
N/A
The investigation focuses on the propriety of R1 RCM’s financial disclosures.
On Oct. 16, 2023, financial fraud investigator Jehoshaphat Research published a scathing forensic report accusing R1 RCM of engaging in misrepresentative accounting and calling its stock “practically uninvestible today.”
Among other matters, Jehoshaphat accused R1 RCM of engaging in “aggressive mark-to-model revenue recognition creating most of the revenue growth in the company today, creatively deflat[ing] expenses that inflate Adjusted EBITDA by approximately 55%, potentially systematic under-reserving for customer bad debts” and “increasingly aggressive revenue recognition practices to pull forward revenues[.]”
In response, the price of R1 RCM shares fell about 8% on Oct. 16, 2023.
